Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Androtriol Injection in Cerebral Small Vessel Disease
CTR20202313Phase 2Terminated
- Sponsor
- Guangzhou Sceptre Pharmaceutical Technology
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of androtriol in Cerebral Small Vessel Disease (CSVD), ischemic stroke, sponsored by Guangzhou Sceptre Pharmaceutical Technology. Started Nov 2020; status: terminated.
02
Drugs
androtriol
03
Conditions
Cerebral Small Vessel Disease (CSVD)ischemic stroke
Beyond the preview
Go deeper on CTR20202313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202313.